Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study is designed to find the optimum radiation dose and number of cycles for an ABVD chemotherapy combined with an involved field irradiation. It is to be tested whether the reduction from 4 to 2 cycles of ABVD and/or the reduction of the radiation dose from 30 to 20 Gy is feasible without a loss of efficacy.


Options:
A: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Intervention Type: DRUG; Name: Adriamycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: DTIC; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: RADIATION; Name: 30 Gy IF-RT; Assigned to Arm(s): Arm A, Arm C | Intervention Type: RADIATION; Name: 20 Gy IF-RT; Assigned to Arm(s): Arm B, Arm D
B: Arm Label: Brentuximab vedotin; Type: EXPERIMENTAL; Interventions: Drug: brentuximab vedotin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: brentuximab vedotin; Assigned to Arm(s): Brentuximab vedotin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group 1 (favorable prognosis); Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Drug: ABVD regimen, Drug: carmustine, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: methylprednisolone, Drug: vincristine sulfate, Drug: vindesine | Arm Label: Group 2 (intermediate prognosis); Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Drug: ABVD regimen, Drug: carmustine, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: methylprednisolone, Drug: vincristine sulfate, Drug: vindesine | Arm Label: Group 3 (poor prognosis); Type: EXPERIMENTAL; Interventions: Drug: carmustine, Drug: cisplatin, Drug: cytarabine, Drug: dexamethasone, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: gemcitabine hydrochloride, Drug: ifosfamide, Drug: melphalan, Drug: methylprednisolone, Drug: mitoguazone, Drug: vindesine, Drug: vinorelbine tartrate, Procedure: allogeneic hematopoietic stem cell transplantation, Procedure: autologous hematopoietic stem cell transplantation | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: ABVD regimen; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: carmustine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: mitoguazone; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: vinorelbine tartrate; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: PROCEDURE; Name: allogeneic hematopoietic stem cell transplantation; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Group 3 (poor prognosis)
D: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Involved Field Radiotherapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Other: No further treatment | Intervention Type: RADIATION; Name: Involved Field Radiotherapy; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: No further treatment; Assigned to Arm(s): Arm II

Answer: A